Recombinant Human CEACAM-5/CD66e Fc Chimera Protein, CF

When Recombinant Human CEACAM-5/CD66e Fc Chimera (10449-CM) is immobilized at 0.5 μg/mL (100 μL/well), Recombinant Human Galectin-4 (1227-GA) binds with an ED50 of 10-90 ng/mL.

2 μg/lane of Recombinant Human CEACAM-5/CD66e Fc Chimera Protein (Catalog # 10449-CM) was resolved withSDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized byCoomassie® Blue staining, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CEACAM-5/CD66e Fc Chimera Protein, CF Summary

• Additional Information: HEK293 Expressed Protein
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CEACAM-5/CD66e Fc Chimera (Catalog # 10449-CM) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Galectin-4 (Catalog # 1227-GA) binds with an ED₅₀ of 10-90 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CEACAM-5/CD66e protein
  

  Human CEACAM-5/CD66e (Lys35-Ala685) Accession # NP_004354.3	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_004354.3
• N-terminal Sequence: Lys35
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 96 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 135-175 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CEACAM-5/CD66e Fc Chimera Protein, CF

• Carcinoembryonic antigen
• carcinoembryonic antigen-related cell adhesion molecule 5
• CD66e antigen
• CD66e
• CEA
• CEACAM5
• CEACAM-5
• CEACD66e
• DKFZp781M2392
• Meconium antigen 100

Background

CEACAM-5, also known as CEA, CD66e and Psg30, belongs to the large family of CEACAM and pregnancy specific glycoproteins. CEACAM family members are highly glycosylated with varying arrangements of IgV-like and IgC-like regions in their extracellular domains (ECD) and can be expressed as transmembrane, glycophosphatidyl inositol (GPI) linked or soluble proteins (1-3).  CEACAM-5 consists of an N-terminal Ig-like V-set domain followed by six Ig-like C2-set domains and a GPI anchor (2, 4, 5). While the mature ECD of human CEACAM-5 shares 26% amino acid identity with mouse CEACAM-5, it remains unclear if these molecules are direct orthologs (6). CEACAM-5, expressed primarily by epithelial cells, functions as a calcium-independent adhesion molecule through homophilic and heterophilic interactions with CEACAM-1 (1, 7). CEACAM-5 is restricted to the apical face of intestinal epithelial cells in the adult but is more diffuse during embryonic development and in tumors (8). This is consistent with a role in the development and maintenance of epithelial architecture. CEACAM-5 is up-regulated in a wide variety of human tumors, promoting tumor cell migration, invasion, adhesion, and metastasis, and has been used as a cancer marker (8, 9). It also contributes to tumor formation by maintaining cellular proliferation in the presence of differentiation stimuli, and by blocking apoptosis following loss of ECM anchorage (anoikis) (10, 11). The GPI anchoring of CEACAM-5 can be released by GPI-PLD, resulting in a soluble molecule that also promotes tumor metastasis (12). Cell surface expression of CEACAM-5 on tumor cells prevents the adhesion of CEACAM-1 expressing NK cells and provides protection from NK-mediated lysis (8). CEACAM-5 was shown to bind galectin-4 and by surface plasmon resonance and coimmunoprecipitated with galectin-4 in human colon adenocarcinoma LS174T cell lysates  (13). CEACAM-5 also binds a subset of Neisseria opacity proteins (Opa) and E. coli adhesion proteins (14, 15). These interactions trigger clustering of the lipid raft-localized CEACAM-5 to sites of pathogen contact (15, 16).

1. Zebhauser, R. et al. (2005) Genomics 86:566.
2. Hammarstrom, S. (1999) Semin. Cancer Biol. 9:67.
3. Chan, et al. (2007) Curr Oncol. 14:70.
4. Schrewe, H. et al. (1990) Mol. Cell. Biol. 10:2738.
5. Hefta, S.A. et al. (1988) Proc. Natl. Acad. Sci. 85:4648.
6. Hance, K.W. et al. Mutat Res. (2005) 576:132.
7. Stern, N. et al. (2005) J. Immunol. 174:6692.
8. Beauchemin N. et al. (2013) Cancer Metastasis Rev. 32:3.
9. Blumenthal, R.D. et al. (2005) Cancer Res. 65:8809.
10. Screaton, R.A. et al. (1997) J. Cell Biol. 137:939.
11. Ordonez, C. et al. (2000) Cancer Res. 60:3419.
12. Yamamoto, Y. et al. (2005) Biochem. Biophys. Res. Commun. 333:223.
13. Ideo, H. et al. (2005) J Biol Chem. 280:4730.
14. Martin, J.N. et al. (2016) Biochemistry. 55:4286.
15. Berger, C.N. et al. (2004) Mol. Microbiol. 52:963.
16. Tchoupa, A.K. et al. (2014) Cell Commun Signal. 12:27.

Bioinformatics

• Uniprot:
  • NP_004354.3()